K. Ruhm

Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options

L. Zender, K. Nikolaou, G. Tabatabai, 2020, JCO precision oncology.

Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approaches.

C. Schroeder, S. Ossowski, T. Haack, 2022, European journal of cancer.

Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma

A. Poso, K. Nikolaou, M. Claassen, 2021, npj Precision Oncology.

Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system

C. Lengerke, O. Kohlbacher, S. Nahnsen, 2023, Neuro-oncology advances.

The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma

T. Kronenberger, Stefan A. Laufer, K. Ruhm, 2024, Nature communications.